KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Inventory Average (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Inventory Average for 11 consecutive years, with $128.3 million as the latest value for Q4 2023.

  • On a quarterly basis, Inventory Average changed N/A to $128.3 million in Q4 2023 year-over-year; TTM through Dec 2023 was $128.3 million, a N/A change, with the full-year FY2024 number at $134.7 million, up 18.33% from a year prior.
  • Inventory Average was $128.3 million for Q4 2023 at Halozyme Therapeutics, up from $103.8 million in the prior quarter.
  • In the past five years, Inventory Average ranged from a high of $128.3 million in Q4 2023 to a low of $50.8 million in Q1 2022.
  • A 4-year average of $71.5 million and a median of $58.8 million in 2020 define the central range for Inventory Average.
  • Peak YoY movement for Inventory Average: dropped 14.63% in 2022, then surged 104.24% in 2023.
  • Halozyme Therapeutics' Inventory Average stood at $59.2 million in 2020, then fell by 7.23% to $54.9 million in 2021, then dropped by 7.48% to $50.8 million in 2022, then skyrocketed by 152.31% to $128.3 million in 2023.
  • Per Business Quant, the three most recent readings for HALO's Inventory Average are $128.3 million (Q4 2023), $103.8 million (Q1 2023), and $50.8 million (Q1 2022).